Clinical needs for hematopoietic growth factors: old and new.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer Investigation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/07357909609076906PMID 8951365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia.

  1996cited by this paper
• Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.

  1995cited by this paper
• Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.

  1994cited by this paper
• Cytokine Intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL‐1/GM‐CSF

  1994cited by this paper
• Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

  1994cited by this paper
• Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit on bone marrow cells.

  1994cited by this paper
• Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis

  1994cited by this paper
• c-Mpl ligand is a humoral regulator of megakaryocytopoiesis

  1994cited by this paper
• Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin

  1994cited by this paper
• Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand

  1994cited by this paper
• Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor.

  1994cited by this paper
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

  1994cited by this paper
• Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines.

  1994cited by this paper
• Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.

  1994cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• The macrocyclic lactone protein kinase C activator, bryostatin 1, either alone, or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation.

  1994cited by this paper
• In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care

  1994cited by this paper
• Hope for treatment of thrombocytopenia.

  1994cited by this paper
• IL-12 protects bone marrow from and sensitizes intestinal tract to ionizing radiation.

  1994cited by this paper
• Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes

  1994cited by this paper
• Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial

  1994cited by this paper
• Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.

  1994cited by this paper
• Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

  1994cited by this paper
• Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.

  1994cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Modulation by bryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors.

  1993cited by this paper
• The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.

  1993cited by this paper
• Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

  1993cited by this paper
• Interleukin-6.

  1993cited by this paper
• Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.

  1993cited by this paper
• Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high‐dose chemotherapy plus granulocyte‐macrophage colony‐stimulating factor a randomized trial

  1993cited by this paper
• Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.

  1993cited by this paper
• Interleukin-7: biology and potential clinical applications.

  1993cited by this paper
• Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.

  1993cited by this paper
• Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.

  1993cited by this paper
• Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.

  1993cited by this paper
• Granulocyte colony-stimulating factor treatment of leucopenia during fractionated radiotherapy.

  1993cited by this paper
• Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy.

  1993cited by this paper
• The Frequency of Red Cell Transfusion for Anemia in Patients Receiving Chemotherapy A Retrospective Cohort Study

  1993cited by this paper
• Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.

  1993cited by this paper
• Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

  1993cited by this paper
• Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 1.

  1993cited by this paper
• Evaluating drugs after their approval for clinical use.

  1993cited by this paper
• Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.

  1993cited by this paper
• Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.

  1993cited by this paper
• Peripheral Blood Stem Cell Mobilization by Chemotherapy With and Without Recombinant Human Granulocyte Colony-Stimulating Factor

  1992cited by this paper
• Interleukin-8 as a macrophage-derived mediator of angiogenesis.

  1992cited by this paper
• A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma.

  1992cited by this paper
• Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

  1992cited by this paper
• A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.

  1992cited by this paper
• Regulation of human cytolytic lymphocyte responses by interleukin-12.

  1992cited by this paper
• Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.

  1992cited by this paper
• Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: implications for discontinuation of antibiotics and early discharge from the hospital.

  1992cited by this paper
• Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.

  1992cited by this paper
• Neutrophil chemotactic factors produced by a cell line from thyroid carcinoma.

  1992cited by this paper
• Interleukin‐8 induces changes in human neutrophil actin conformation and distribution: relationship to inhibition of adhesion to cytokine‐activated endothelium

  1992cited by this paper
• Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.

  1992cited by this paper
• Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma

  1992cited by this paper
• Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation.

  1992cited by this paper
• Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas.

  1992cited by this paper
• Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.

  1992cited by this paper
• Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

  1992cited by this paper
• IL6 and the acute phase reaction.

  1992cited by this paper
• Chemotactic factors, passive invasion and metastasis of cancer cells.

  1992cited by this paper
• Anti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivo

  1992cited by this paper
• Stem cell factor enhances proliferation, but not maturation, of murine megakaryocytic progenitors in serum-free culture.

  1992cited by this paper
• Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.

  1992cited by this paper
• Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.

  1992cited by this paper
• At age 2, gene therapy enters a growth phase.

  1992cited by this paper
• Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

  1992cited by this paper
• Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor.

  1992cited by this paper
• Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.

  1992cited by this paper
• No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation.

  1992cited by this paper
• Recombinant human granulocyte‐macrophage colony‐stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double‐blind, placebo‐controlled trial

  1992cited by this paper
• Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL.

  1992cited by this paper
• Pathogenetic role of Epstein-Barr virus in malignant lymphomas that develop in immunocompromised patients.

  1992cited by this paper
• Inhibition of colon and breast carcinoma cell growth by interleukin-4.

  1992cited by this paper
• A Controlled Trial of Recombinant Human Granulocyte-macrophage Colony-stimulating Factor After Total-body Irradiation, High-dose Chemotherapy, and Autologous Bone-marrow Transplantation for Acute Lymphoblastic-leukemia Or Malignant-lymphoma

  1992cited by this paper
• Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.

  1992cited by this paper
• Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes

  1991cited by this paper
• Interleukin 4 Alone and with γ-Interferon or α-Tumor Necrosis Factor Inhibits Cell Growth and Modulates Cell Surface Antigens on Human Renal Cell Carcinomas

  1991cited by this paper
• Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas.

  1991cited by this paper
• Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

  1991cited by this paper
• Recombinant Human Erythropoietin (rHuEPO) for the Treatment of the Anemia of Cancer.

  1991cited by this paper
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

  1991cited by this paper
• Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

  1991cited by this paper
• Generation and analysis of interleukin-4 deficient mice.

  1991cited by this paper
• GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.

  1991cited by this paper
• Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.

  1991cited by this paper
• Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor.

  1991cited by this paper
• Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles.

  1991cited by this paper
• Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

  1991cited by this paper
• Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes.

  1991cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression.

  1991cited by this paper
• Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide- enhanced radioresistance

  1991cited by this paper
• Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation.

  1991cited by this paper
• The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin

  1990cited by this paper

• The evolving role of bisphosphonates.

  2001cites this paper
• Effects of granulocyte‐macrophage colony stimulating factor (GM‐CSF) in vivo on cytokine production and proliferation by spleen cells

  2001cites this paper
• Administration of recombinant human stem cell factor (rhSCF) and granulocyte-colony stimulating factor (rhG-CSF) to maternal and fetal rhesus monkeys (Macaca mulatta).

  1999cites this paper